Terbinafine-induced hepatic failure requiring liver transplantation

✍ Scribed by Zeeshan Perveze; Mark W. Johnson; Raymond A. Rubin; Marty Sellers; Carlos Zayas; Jody L. Jones; Rosemary Cross; Kimberly Thomas; Bradley Butler; Roshan Shrestha

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 198 KB
• Volume: 13
• Category: Article
• ISSN: 1527-6465
• DOI: 10.1002/lt.21034

✦ Synopsis

Drug-induced liver disease accounts for about 50% of acute or subacute liver failure in the United States. United Network of Organ Sharing (UNOS) data suggest 8%-20% of liver transplantation in this country per year is for fulminant liver failure due to drugs. Even though the most common medication implicated in acute liver injury is acetaminophen (75%), there are numerous other drugs that are responsible for acute and chronic liver injury. A variety of antifungal medications are known to cause a wide range of liver injury from a mild hepatocellular-cholestatic injury pattern to acute/subacute liver failure. Terbinafine is one of the antifungals that have been associated with such liver injuries. We report a case of terbinafine-induced severe liver failure requiring liver transplantation.